XBiotech Inc. (XBIT): Price and Financial Metrics

XBiotech Inc. (XBIT)

Today's Latest Price: $17.11 USD

0.35 (-2.00%)

Updated Oct 30 4:00pm

Add XBIT to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 384 in Biotech

See all "A" rated Strong Buy stocks

XBIT Stock Summary

  • With a price/earnings ratio of 0.74, XBiotech Inc P/E ratio is greater than that of about merely 0.41% of stocks in our set with positive earnings.
  • For XBIT, its debt to operating expenses ratio is greater than that reported by only 0.36% of US equities we're observing.
  • Over the past twelve months, XBIT has reported earnings growth of -3,258.61%, putting it ahead of just 0.45% of US stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to XBiotech Inc are WATT, IMAB, NVTA, PRTA, and GWRE.
  • XBIT's SEC filings can be seen here. And to visit XBiotech Inc's official web site, go to www.xbiotech.com.

XBIT Stock Price Chart Interactive Chart >

Price chart for XBIT

XBIT Price/Volume Stats

Current price $17.11 52-week high $26.40
Prev. close $17.46 52-week low $8.72
Day low $16.91 Volume 67,300
Day high $17.78 Avg. volume 391,487
50-day MA $19.00 Dividend yield N/A
200-day MA $15.94 Market Cap 496.00M

XBiotech Inc. (XBIT) Company Bio

XBiotech Inc. is a clinical-stage biopharmaceutical company, engages in discovering and developing “True Human™” monoclonal antibodies for treating various different diseases. The company was founded in 2005 and is based in Austin, Texas.

XBIT Latest News Stream

Event/Time News Detail
Loading, please wait...

XBIT Latest Social Stream

Loading social stream, please wait...

View Full XBIT Social Stream

Latest XBIT News From Around the Web

Below are the latest news stories about XBiotech Inc that investors may wish to consider to help them evaluate XBIT as an investment opportunity.

XBiotech +11% on FDA's approval on convalescent plasma for Covid treatment

XBiotech (XBIT) announces that FDA issued an emergency use authorization for COVID-19 Convalescent Plasma as a COVID-19 treatment, thus opening door for the company’s antibody screening technology.The company collaborated with BioBridge Global to develop a test to accurately detect human antibodies present in patient blood that specifically attack the COVID-19 virus.BioBridge Global...

Seeking Alpha | August 24, 2020

XBiotech, AstraZeneca rise; Churchill Downs, Gilead fall

Stocks that moved heavily or traded substantially Monday: XBiotech, AstraZeneca rise; Churchill Downs, Gilead fall

ABC News | August 24, 2020

XBiotech Discovers COVID-19 Candidate Therapy

The Company has Identified Highly Targeted Anti-COVID-19 True Human Antibodies from Immune Donor Blood

GlobeNewswire | August 17, 2020

XBiotech Achieves Milestone for Production of its New Potential Blockbuster Anti-IL-1⍺ Therapy

After Sale of its Previous Anti-IL-1a True Human Antibody, Company Now Has Production Cell to Manufacture New Molecule for Launch of Clinical Studies in 2021

GlobeNewswire | July 22, 2020

XBiotech Announces Discovery that Blocking Interleukin-1a Reduces Brain Injury and Neurological Deficit After Stroke

Antibody Therapy Targeting Interleukin-1a significantly reduced stroke related brain injury in animals and points to new potential blockbuster therapy

GlobeNewswire | July 14, 2020

Read More 'XBIT' Stories Here

XBIT Price Returns

1-mo -9.18%
3-mo 17.68%
6-mo 11.61%
1-year 51.68%
3-year 307.38%
5-year 21.61%
YTD -8.33%
2019 267.42%
2018 28.93%
2017 -61.07%
2016 -6.90%
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.7101 seconds.